You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Targeted Therapy for Breast Cancer

    SBC: A&G PHARMACEUTICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side effects induced in patients and insufficient efficacy, particularly for patients with metastatic disease. Targeted cancer therapy is designed to treat only the cancer cells and minimize damage to healthy ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. A COMPANION DIAGNOSTIC FOR PROGNOSIS OF KIDNEY CANCER

    SBC: 20 20 Genesystems Inc            Topic: NCI

    This contract was awarded by the National Cancer Institute's Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) Program under the funding opportunity "Contract Topic: 277 Companion Diagnostics: Predictive and Prognostic Tests Enabling Personalized Medicine in Cancer Therapy."

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm

    SBC: 20 20 Genesystems Inc            Topic: NCI

    DESCRIPTION (provided by applicant): The promise of personalized medicine relies on the development of diagnostic tests to categorize patients within small cohorts who will benefit from specific treatments. 20/20 GeneSystems, Inc. (20/20) is a small business concern focused on the development of diagnostics for personalized medicine. Towards this end, 20/20 has developed, with the support of the N ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. TB Diagnostics at the Point of Care

    SBC: AKONNI BIOSYSTEMS INC            Topic: NIBIB

    DESCRIPTION (provided by applicant): Of all diseases, Tuberculosis (TB) represents one of, if not, the greatest health disparity between whites and minorities [1]. To be specific, for every TB-infected white person in the United States, there are an estimated 9 African-Americans, 8 Latinos, 6 Native Americans, 23 Asians, and 21 Native Hawaiian/Pacific Islanders with this disease [2]. Compounded wi ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Combination Treatment of tPA and Apyrase for Stroke

    SBC: APT THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. Using a protein informatics approach, we have successfully engineered a human apyrase which exhibits significantly higher enzymatic activity and platelet inhibition than the wild-type ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Combination Therapy of Aspirin and Apyrase for Stroke

    SBC: APT THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. We will validate hypothesis that in thromboembolic model of stroke in rats, combination tre ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. TGF-beta Antagonists for Accelerating Wound Healing

    SBC: AUXAGEN, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Every year in the United States, gt1.25 million people suffer from burns, 6.5 million have chronic skin ulcers caused by pressure, venous stasis or diabetes mellitus and 0.25 million have keloids sufficiently severe to require surgery. Burn treatment costs 1.8 billion per year in the US. The treatment of persons with chronic skin ulcers costs 13 billion per y ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a novel human rhinovirus vaccine

    SBC: BIOLOGICAL MIMETICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Human Rhinoviruses (HRV) cause approximately one third of the 60 million cases of common cold each year in the US and therefore are one of the most economically important human diseases of developed countries. Although rhinoviruses are not generally considered killer viruses, more recent studies have shown that rhinoviruses are a significant source of hosp ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. New Needle for Two-Needle Hemodialysis

    SBC: BIOMEDICAL ENTERPRISES INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Studies performed with phase I SBIR grants 1R43DK55385-01A1 and 1 R43 DK59062-01A1 and phase II SBIR grants 2R44DK059062-02A1 and 5R44DK059062-04 have demonstrated the following: a) A new hemodialysis(HD) venous needle (NVN) with three jets is hemodynamically superior to the current venous needle (CVN) because it decreases the velocity of the vascular access ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Device to Improve Treatment of Colorectal Cancer Using O2 Dependent Phosphorescen

    SBC: SURGISENSE CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Anastomotic failure is one of the most feared complications of gastrointestinal surgery due to the resultant morbidity and mortality. Failure of an anastomosis, or intestinal junction, can cause a spectrum of morbidities to the patient including local abscess formation - requiring procedural drainage, tumor recurrence, debilitating pain, dysfunctional defecatio ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government